Loading...
Loading...
Stifel Nicolaus initiated its coverage on Oncolytics Ciotech
ONCY with a Buy rating and a price target of $6 a share.
Stifel Nicolaus commented, "We view ONCY's sole clinical candidate Reolysin as a compelling potential treatment for ~60% of cancers. Reolysin is a specific strain of a naturally occurring virus that only replicates in cancer cells with an activated Ras signaling pathway, a key metabolic pathway in cell metabolism that is mutated in over 60% of all carcinomas. Reolysin has demonstrated compelling efficacy in numerous oncology indications and as a live virus Reolysin's main side effect is "viral syndrome", not the typical side effects of chemotherapy."
Oncolytics Ciotech closed at $2.76 on Wednesday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in